Saint-Priest-en-Jarez

• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting
  2023-505046-26-00 5 2026-05-07 Colon carcinoma
• Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Plac … Recruiting
  2023-507801-32-00 6 2026-04-22 Isolated Subsegmental Pulmonary Embolism
• metastatic colorectal cancer Recruiting
  2023-504831-42-00 5 2025-06-27 patient with colorectal cancer with hepatic metastasis
• A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i … Recruiting
  2024-514899-41-00 4 2024-10-31 Breast cancer
• PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge … Recruiting
  2024-511070-68-01 5 2024-09-24 Ampullary adenocarcinoma
• HydroxyChloroquine as steroid-sparing Agent in Extra-pulmonary SARcoidosis. A multicenter, prospective, placebo-controlled, randomized trial … Recruiting
  2022-502155-65-00 5 2024-07-30 Extra pulmonary sarcoidosis
• “Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent n … Recruiting
  2023-505112-38-00 11 2024-07-01 recently active non-infectious intermediate, posterior, and pan-uveiti
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16 Ulcerative Colitis
• Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV … Recruiting
  2023-506232-32-00 9 2024-04-08 Multiple recurrences of Clostridioides difficile infection treated wit
• Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenoc … Recruiting
  2023-506885-30-00 5 2024-03-26 Adult patients with intermediate low or mid rectal adenocarcinoma to b
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• ERASE PH-COPD Recruiting
  2022-500862-93-00 5 2024-02-01 Pulmonary Hypertension
• Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid l … Recruiting
  2023-504555-27-00 5 2023-11-28 Myelodysplastic syndrome (MDS)
• FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul … Recruiting
  2022-502019-12-00 5 2023-09-14 acute myeloid leukemia
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient … Recruiting
  2022-501810-77-00 5 2023-09-01 Relapsed or Refractory Marginal Zone Lymphoma
• Human recombinant interferon gamma in the treatment of ventilator-acquired pneumonia in ICU patients. IGNORANT study Recruiting
  2022-502229-16-00 5 2023-06-19 Ventilator acquired pneumonia
• THINK - intensification of blood pressure lowering Therapeutics based on diuretics versus usual management for uncontrolled Hypertension IN … Recruiting
  2022-501494-39-00 5 2023-03-28 Uncontrolled Hypertension IN patients with moderate to severe chronic
• EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co … Recruiting
  2022-501335-16-00 10 2023-01-16 Interstitial lung disease
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome

Showing 1–24 of 49 trials